Although sufficient data are not yet available to fully assess the efficacy and safety of anti-IL-1 molecules in patients with inflammatory disorders other than rheumatoid arthritis, new data are promising.[60]Moltó A, Olivé A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine. 2010 Mar;77(2):102-7.
http://www.ncbi.nlm.nih.gov/pubmed/20045371?tool=bestpractice.com
[61]Dumusc A, Pazar Maldonado B, Benaim C, et al. Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: A randomized controlled double-blinded pilot study. Joint Bone Spine. 2021 Mar;88(2):105088.
https://www.doi.org/10.1016/j.jbspin.2020.105088
http://www.ncbi.nlm.nih.gov/pubmed/33445133?tool=bestpractice.com